Is it Possible to use Anthracyclines in Patients Older than 70 Years? Contra

Dees E.C. , O'Reilly , Goodman S.N. : A prospective pharmacologic evaluation of age-related toxicityof adjuvant chemotherapy in women with breast cancer. Cancer Invest, 18: 521–529, 2000

Ibrahim N.K. , Frye dK , Buzdar A.U. : Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Arch Intern Med, 156: 882–886; 1996.

Cupples L.A. , D'Agostino R.B. : Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennal measurements: Framingham heart study, 30-yeras follow-up. In: Kannel WB , Wolf PA , Garrison RT (eds), the Framingham study: an epidemiological investigation of cardiovascular diseases. (NIH no. 87-2703) National Heart, Lung and Blood Institute, 1987.

Von Hoff D.D. , Layard M.W. , Basa P. : Risk factors for doxorubicin-induced congestive heart failure. Ann Int Med 91: 710–717, 1979.

Venturini M. , Michelotti A. , Del Mastro L. : Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 14: 3112–3120, 1996.

Ibrahim N.K. , Hortobagyi G.N. , Ewer M. : Doxorubicin-in-duced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. Cancer Chemother Pharmacol, 43: 471–478, 1999.

Van der Maase H. , Hansen S.W. , Roberts J.T. : Gemcitabine and Cisplatin versus methotrexate, vinblastine, doxorubicin, and cislatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol, 17: 3068–3077, 2000.

Sonneveld P. , De Ridder M. , Van der Lelie H. : Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol, 13: 2530–2539, 1995.

Tirelli U. , Errante D. , Van Glabbeke M. : CHOP is the standard regimen in patients > 70 years of age with intermediate-grade and high-grade non-Hodgkin lymphoma: results of a randomized study of the european Organization for Research and Treatment of Cancer lymphoma cooperative study group. J Clin Oncol, 16: 27–34, 1998.

Mainwaring P.N. , Cunningham D. , Gregory W. : Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO. Blood, 97: 2991–2997, 2001.